Skip to content

The Effect of Group-based Lifestyle Medicine Intervention and CBT on Depressive Symptoms

The Effect of Group-based Lifestyle Medicine Intervention and Cognitive Behavioural Therapy on Depressive Symptoms: A Pilot Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05716464
Enrollment
40
Registered
2023-02-08
Start date
2023-02-28
Completion date
2024-08-31
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, Lifestyle medicine, Cognitive-behavioral therapy for depression, Randomised controlled trial

Brief summary

The objective of this randomized controlled trial is to evaluate and compare the efficacy of group-based lifestyle medicine intervention and cognitive-behavioral therapy for depression (CBT-D) for Chinese adults with depressive symptoms. Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). Around 40 eligible participants aged between 18 to 65 with depression (Patient Health Questionnaire-9 \[PHQ-9\] ≥ 10) will be randomly assigned to the Lifestyle Medicine group (LM group), or the CBT-D group in a ratio of 1:1. Participants in both groups will receive interventions either through lifestyle medicine intervention or CBT-D group therapy for 6 consecutive weeks. The outcomes of interest will include depressive, anxiety, and insomnia symptoms, quality of life, functional impairment, and health-promoting behaviours at baseline (week 0), immediate (week 7) and 3-month post-intervention assessments (week 19). Treatment credibility and acceptability will be collected before and immediately after treatment.

Interventions

BEHAVIORALLifestyle medicine intervention

The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.

BEHAVIORALCognitive-behavioral therapy for depression (CBT-D)

The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Chinese adults reside in Hong Kong; 2. Aged between 18 to 65 years; 3. Have a Patient Health Questionnaire-9 (PHQ-9) score ≥ 10, indicating at least moderate level of depressive symptoms; 4. Able to read and understand Chinese/Cantonese and are fluent in Cantonese; 5. Willing to provide informed consent and comply with the trial protocol.

Exclusion criteria

1. Received psychotherapy for depression in the past 6 months; 2. A change in psychotropic drugs that target depression within 2 weeks before the baseline assessment; 3. A PHQ-9 question 9 score higher than 2, indicating a moderate level of suicidal risk that requires active crisis management (referral information to professional mental health services will be provided); 4. Currently participating in another intervention study that may potentially improve mental health; 5. Self-disclosure of any psychiatric, medical or neurocognitive disorder(s) that makes participation unsuitable based on the team's clinical experience or interferes with adherence to the lifestyle modification (e.g., where exercise is not recommended by physicians); 6. Pregnancy; 7. Hospitalization.

Design outcomes

Primary

MeasureTime frameDescription
Change in the Patient Health Questionnaire (PHQ-9)Baseline, immediate post-treatment, and 12-week follow-upThe PHQ-9, a 9-item questionnaire used for screening, diagnosing, monitoring, and measuring the severity of depression, which scores each of the nine DSM-IV criteria as 0 (not at all) to 3 (nearly every day).

Secondary

MeasureTime frameDescription
Change in the Insomnia Severity Index (ISI)Baseline, immediate post-treatment, and 12-week follow-upISI is a 7-item scale designed to evaluate perceived insomnia severity. Ratings on the 5-point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeably of impairment attributed to the sleep problem, and level of distress caused by the sleep problem.
Change in the Short Form (Six-Dimension) Health Survey (SF-6D)Baseline, immediate post-treatment, and 12-week follow-upSF-6D is a preference-based single index measure of health. A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality.
Change in the Health-Promoting Lifestyle Profile (HPLP-II)Baseline, immediate post-treatment, and 12-week follow-upThe 52-item HPLPII is composed of a total scale and six subscales to measure behaviors in the theorized dimensions of health-promoting lifestyle: spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility, and stress management.
Change in the Generalized Anxiety Disorder 7-Item Scale (GAD-7)Baseline, immediate post-treatment, and 12-week follow-upThe GAD-7, a 7-item questionnaire used for screening, diagnosing, monitoring, and measuring the severity of anxiety over the past two weeks on a 4-point scale, 0 (not at all) to 4 (nearly every day).
Change in the Credibility-Expectancy Questionnaire (CEQ)Baseline and immediate post-treatmentThe 6-item CEQ yielded ratings of treatment credibility, acceptability/satisfaction, and expectations for success. Specific wording referencing anxiety was changed to refer to depression.
Change in the International Physical Activities Questionnaire - Chinese version (IPAQ-C)Baseline, immediate post-treatment, and 12-week follow-upParticipants' sitting time, walking time and moderate and vigorous physical activity are assessed by 5 questions from a short form of the International Physical Activity Questionnaire - Chinese version a short form of the IPAQ-C. The questions include: On a typical weekday in the last 7 days, how many hours per day did you typically spend sitting?; On a typical weekend in the last 7 days, how many hours per day did you typically spend sitting?; During the last 7 days, on how many days did you do at least 10 minutes moderate physical activity/vigorous physical activity/walking?; How much time did you usually spend doing the moderate physical activity /vigorous physical activity/walking on one of those days?; and How much time did you usually spend engaging in physical activity while seated and standing on one of those days?
Change in the Treatment Acceptability and Adherence Scale (TAAS)Baseline and immediate post-treatmentTAAS is a self-reported, ten-item questionnaire that is rated by a seven-point Likert scale from 1 to 7, and it aims at evaluating the clients' attitude toward the treatment sessions by four domains, including acceptability, adherence, drop-out, and distress. Specific wording referencing anxiety was changed to refer to depression.
Change in the Sheehan Disability Scale (SDS)Baseline, immediate post-treatment, and 12-week follow-upSDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.

Contacts

Primary ContactVivian Lai
vivian.lai@link.cuhk.edu.hk3943 6575
Backup ContactVincent Wong
vincentwongWH@link.cuhk.edu.hk3943 6575

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026